Hosted on MSN1d
Moderna: A Generational Opportunity for Investors in 2025
As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...
America's Gold: Mark It to Market?
Gold Spot US Dollar, Gold Futures, VanEck Gold Miners ETF. Read Stewart Thomson's latest article on Investing.com ...
Hosted on MSN2d
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?
Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...
Morgan Stanley Keeps Their Hold Rating on Moderna (MRNA)
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...
CureVac Earns Repeat Recognition by LexisNexis as One of the World's Top Innovators
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolioThe company holds one of th ...
Tesla (TSLA) Is the Best Stock to Short, Says Wolfe Research
Electric vehicle maker Tesla (TSLA) has been named the best stock for investors to short right now by Wolfe Research.Maximize ...
Moderna, Inc. (MRNA) Stock Forecasts
Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is r ...
Moderna, Inc.: Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...